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Abstract 
Background: Chromatin is an extraordinarily complex structure. Much of this complexity results from the presence 
of numerous histone post‑translational modifications and histone variants. Alterations in the patterns of histone post‑
translational modifications are emerging as a feature of many types of cancer and have been shown to have prognos‑
tic value.
Results: We have applied a liquid chromatography/mass spectrometry‑based approach to comprehensively charac‑
terize the histone proteome in primary samples from chronic lymphocytic leukemia (CLL) patients, as well as bladder 
and breast cancer cell culture models. When compared to non‑malignant CD19+ B cells from healthy donors, the CLL 
histone proteome showed a distinct signature of differentially expressed species, spanning all the histones studied 
and including both post‑translationally modified species and unmodified, non‑allelic replication‑dependent histone 
isoforms. However, the large changes in histone H3 and H4 that are characteristic of many cancer types were not 
observed. One of species of H2A (mass = 14,063 Da) was the most strongly associated with time to treatment in CLL 
patients. CLL patient samples also demonstrated histone profiles that were distinct from those of the bladder and 
breast cancer cells.
Conclusions: Signatures of histone profiles are complex and can distinguish between healthy individuals and CLL 
patients and may provide prognostic markers. In addition, histone profiles may define tissue specific malignancies.
Keywords: Histone, Post‑translational modification, Chromatin, Chronic lymphocytic leukemia
© 2015 Singh et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The packaging of eukaryotic genomes with histones to 
form chromatin is essential for the necessary conden-
sation and protection of DNA. Given the central role 
of histones in chromatin, there have been a number of 
studies that have examined histone proteins to identify 
alterations, particularly post-translational modifica-
tions, associated with cancer. Indeed, several of the post-
translational modifications may have clinical utility as 
prognostic markers. For example, decreased levels of his-
tone H4 lysine 16 acetylation (H4 K16Ac) and H4 lysine 
20 trimethylation (H4 K20me3) are found in a number 
of human cancers, while low global levels of histone H3 
lysine 9 dimethylation (H3 K9me2) and H3 lysine 18 
acetylation (H3 K18Ac) predict poorer outcome in pros-
tate, lung, kidney and pancreatic cancer [1–9].
The intricate mechanisms of regulation that involve 
chromatin are largely based on the enormous complexity 
built into this structure. While histone post-translational 
modifications are clearly an important source of com-
plexity, variations in the primary sequences of specific 
histone proteins are also a prime contributor. There are 
two basic groups of histone proteins, the replication-
dependent histones and the replication-independent 
histone variants. The replication-dependent histones are 
encoded by multi-gene families that are found in several 
Open Access
*Correspondence:  parthun.1@osu.edu 
1 Department of Biological Chemistry and Pharmacology, The Ohio State 
University, Columbus, OH 43210, USA
Full list of author information is available at the end of the article
Page 2 of 14Singh et al. Clin Proteom  (2015) 12:22 
distinct clusters in the human genome. The expression 
of these histone genes is tightly coupled to DNA repli-
cation and they serve to package DNA into chromatin 
during DNA replication. The replication-independent 
histone variants, such as histone H3.3 and histone H2AZ, 
are typically expressed constitutively throughout the cell 
cycle and are found as single genes dispersed through-
out the genome. Histone variants can play an important 
role in carcinogenesis, where driver mutations in his-
tone H3.3 have been identified in pediatric glioblastoma 
[10–12].
While primary sequence diversity in histones is often 
thought to be the result of the incorporation of histone 
variants, the multiple replication-dependent histone 
genes do not all encode identical proteins [13, 14]. For 
example, there are 16 genes that code for replication-
dependent histone H2A and they produce 11 distinct 
polypeptides. These histone species will be referred to 
as histone isoforms to distinguish them from the more 
familiar histone variants. The replication-dependent his-
tone isoforms typically vary from each other by a small 
number of amino acids. This high degree of identity 
makes them challenging to study using typical techniques 
that would require the generation of isoform-specific 
antibodies. However, they can be readily resolved by 
LC/MS due to the change in mass (see Additional file 1: 
Tables  S1–S4). The clinical importance of histone iso-
forms is highlighted by recent reports that identified 
alterations in specific histone H2A isoforms in B cells iso-
lated from patients with chronic lymphocytic leukemia 
(CLL) and in estrogen receptor positive breast cancer tis-
sues [15–17].
We have used LC/MS to quantify the relative abun-
dance of every detectable histone species in a large set 
of primary tumor samples. By comparing the histone 
profiles between normal B cells and B cells isolated form 
CLL patients, we have identified a number of specific his-
tone species with levels significantly altered in the CLL 
cells. In addition, histone profiles were correlated with 
clinical data from CLL patients to identify species that 
may warrant further study. The most promising was a 
specific histone H2A species (14,063 MW) where expres-
sion was indicative of a shortened time to treatment. We 
have also comprehensively analyzed histone profiles from 
cell culture models of bladder and breast cancer to deter-
mine whether histone alterations are specific to CLL or 
whether they are a more general feature of cancer cells. 
Interestingly, our analyses indicated that significantly 
decreased levels of histone H4 lysine 16 acetylation are 
not a ubiquitous property of cancer cells. Our studies 
highlight the enormous heterogeneity of histone isoforms 
present in human cells and indicate the importance of 
quantifying the histone proteome to understand the 
impact of chromatin structure on carcinogenesis.
Results
Histones were isolated from CLL patient samples 
(n = 87) or CD19+ cells from healthy volunteers (n = 5) 
by acid extraction. The extracted histones were analyzed 
by LC–MS as described in the methods section. For each 
core histone peak eluting from the LC, we selected a spe-
cific mass range that encompassed all of its isoforms in 
an unmodified state as well as the possible spectrum of 
modifications that could occur. We then tested for differ-
ential expression by determining the relative abundance 
of each molecular species in that mass range between 
CLL patient samples and normal donors as well as among 
varying states of disease aggression in bladder and breast 
cell lines. An overview of our methodology has been 
shown in Additional file 2: Figure S1.
Global changes in histone H2A species in leukemic 
and cancer cells
Chronic lymphocytic leukemia
The unmodified replication-dependent histone H2A 
isoforms have masses that range from 13,817 to 14,102 
(Additional file 1: Table S1). A deconvoluted spectrum of 
H2A from a representative normal CD19+ B cell sample 
is shown in Fig. 1a. Each of the peaks in the spectrum rep-
resents a histone isoform or a post-translationally modi-
fied histone isoform with a defined molecular weight. 
In our previous study (n = 35), we focused on the three 
most abundant forms of H2A, which have molecular 
masses of 14,002, 14,018 and 14,046 Da, and normalized 
each peak to the total amount of histone present in these 
three isoforms [15]. Given the complicated nomenclature 
that has arisen for the replication-dependent histones, 
we will use a systematic nomenclature based on the gene 
name for each isoform. The replication-dependent his-
tone genes are named based on their identity and their 
location in the genome. The first part of the name refers 
to the histone cluster (e.g. HIST1, HIST2 or HIST3), the 
second part indicates the type of histone (e.g. H2A, H2B, 
H3, H4 or H1), and finally, the multiple copies of each 
histone type are designated alphabetically based on their 
order within each cluster (centromere distal to proximal). 
Hence, HIST1H2AC refers to the third histone H2A 
gene in histone cluster 1. We will refer to the protein iso-
forms based on this genomic nomenclature. For exam-
ple, the product of the HIST1H2AC gene will be referred 
to as H2A 1C (for HIST1H2AC) (see Additional file  1: 
Tables  S1–S4 for complete list of genes/protein names). 
Using this nomenclature, we refer to these forms as H2A, 
H2A 1C and H2A 1B/E, respectively. In our previous 
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evaluation, we noted that H2A 1C and H2A 1B/E were 
decreased in CLL compared to non-malignant B cells 
[15]. In our present study, we used a larger pool of patient 
samples and comprehensively measured the amount of 
histone present across the entire region, normalizing 
each peak relative to the total amount of histone. Using 
this approach, we found that a decrease in the relative 
abundance of H2A 1B/E was consistently observed, how-
ever H2A 1C was present at an elevated abundance, on 
average, compared to the normal samples (Fig. 1b). The 
level of H2A 1B/E was highly variable and we observed 
both increased and decreased levels of this isoform in the 
CLL patient samples relative to the healthy controls.
Examination of all detectable H2A isoforms identi-
fied 12 that showed statistically significant changes in 
abundance in the CLL patient samples (Table  1), many 
by more than 2-fold. Based on the molecular masses of 
these peaks, it is not possible to definitively determine 
the identity of these species but they are highly modi-
fied, containing methylation and acetylation, as well as 
the possibility of phosphorylation. In addition, there were 
modest increases in the unmodified forms of canonical 
H2A and H2A 1H (Table 1).
The most significantly altered isoform of H2A had a 
molecular mass of 14,063 Da (Fig. 1c). This mass is com-
patible with post-translationally modified versions of sev-
eral H2A isoforms. For example, this mass is consistent 
with the H2A 1H Me3Ac3Phos1, H2A 2C Me3Ac1Phos1 
or H2A 2A Me1Ac1. This species was easily detect-
able in all of the healthy control samples (Fig.  1c), but 
the CLL patient samples appeared to represent two dis-
tinct groups: one with the majority of patients who had 
Fig. 1 Histone H2A isoforms altered in CLL. a A representative spectrum histone H2A. The peaks that are significantly changed in CLL, bladder and 
breast cancer cells are highlighted with arrows (CLL‑green, bladder‑red and breast‑blue). b Comparison of H2A 1C and H2A 1B/1E in normal B cells vs 
CLL patient B cells. c Representative spectrum showing the presence or absence of the peak with molecular weight 14,063 Da in healthy (top) CLL 
patient (bottom) B cells. d Kaplan–Meier curve showing the comparison of time to treatment in patients with and without the 14,063 Da peak
Page 4 of 14Singh et al. Clin Proteom  (2015) 12:22 
Table 1 Histone isoforms that are modified in CLL samples relative to Normal samples with FDR < 0.05
The molecular weight listed may be attributed to either of the histone isoforms listed or to a mixture of these. Two-fold increases and decreases are indicated with ↑↑ 
or ↓↓, respectively. Increases and decreases that were less than two-fold are indicated with ↑ or ↓, respectively. Increases and decreases where the median expression 
for one of the groups was 0, thus prohibiting calculation of fold-changes, is indicated by  or , respectively
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completely undetectable levels and a second, small group 
with detectable levels. Intriguingly, presence of this spe-
cies was associated with shorter time to treatment and 
was the only species with FDR adjusted p-value <0.10 
(Fig. 1d). It is unclear why higher expression that is closer 
to normal levels would be deleterious and needs further 
study.
Bladder and breast cancer models
To determine which changes in histone profiles observed 
in CLL patients are disease- or tissue-specific and which 
might be more generally indicative of a cancerous state, 
we characterized the complement of histone proteins in 
two solid tumor model systems. The first is a set of cell 
lines that represent a range of histopathologic subtypes 
of bladder cancer. The cells that we have examined are 
normal bladder epithelium, normal bladder epithelial 
cells that have been immortalized with hTERT, a cell 
line derived from a non-invasive bladder cancer (RT4) 
and cell lines derived from invasive bladder cancers (T24 
and UMUC3) [18]. Even though none of the histone spe-
cies met our criteria for statistical significance, we did 
observe that levels of H2A 1C dropped when the nor-
mal bladder epithelial cells became immortalized with 
hTERT, consistent with the recent report that decreased 
levels of H2A 1C expression resulted in increased prolif-
eration of cells in vitro [17].
Two other, less abundant, H2A species also showed 
decreased expression levels as the bladder cells became 
more invasive, including unmodified H2A 2C and an 
acetylated/methylated form of H2A 1J. In addition, one 
species, unmodified H2A 1J, displayed increased levels 
in the more malignant cells (Fig. 2a, b). The presence of 
H2A species with a molecular mass of 14,063  Da that 
was indicative of a poor prognosis in CLL, did not show 
significant changes in the bladder cancer cells suggesting 
that changes in this species may be tissue-specific (Addi-
tional file 1: Table S6a, b).
We also analyzed the histone complement in a set 
of breast cancer cell lines, designated M1, M2, M3 and 
M4, that represent a spectrum of subtypes found with 
this disease, with M1 representing immortalized normal 
breast epithelium, M2 representing premalignant cells, 
M3 representing malignant cells and M4 representing 
highly aggressive metastatic disease [19, 20]. The H2A 
spectrum is highly variable among these cell lines with 
9 isoforms changing significantly (Table 2). Interestingly, 
the levels of H2A 1C and H2A 1B/E displayed a statisti-
cally significant increase as the cells became more tumo-
rigenic. This observation is consistent with the recent 
report that increased levels of H2A 1C are seen in estro-
gen receptor positive breast cancers [16]. Changes in less 
abundant H2A species were also observed, such as the 
mono-methylated form of H2A 1H which decreased in 
abundance as the breast cancer cells became more malig-
nant (Table 2). Notably, the unmodified form of H2A 1J, 
which displayed an increase in abundance in bladder can-
cer cell lines, showed an inverse trend in breast cancer 
cells (Fig. 2c, d). Similarly, the levels of H2A 1H show an 
inverse trend in both breast cancer cells and CLL patients 
Fig. 2 Histone H2A isoforms altered in bladder and breast cancer cells. a Representative spectrum of H2A 1J (molecular weight ~13,847 Da) 
isolated from hTERT immortalized bladder epithelium (hTERT) or the bladder cancer cell lines RT2, T24 and UMUC3 (as indicated). b Relative 
abundance of H2A 1J in the indicated bladder cell lines. Relative abundance is the ratio of the area under curve representing H2A 1J relative to the 
sum of the areas of all the H2A peaks. c Representative spectrum of H2A 1J isolated from the indicated breast cancer cell lines. d Plot of the relative 
abundance of H2A 1J in the indicated breast cancer cell lines determined as described above
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(Tables 1, 2). Given the heterogeneity in different cancers 
and cancer cell lines, mechanistic studies are needed in 
order to precisely identify how these isoforms are inte-
grated into the cancer pathway.
Global changes in histone H2B species in leukemic 
and cancer cells
Chronic lymphocytic leukemia
Replication-dependent histone H2B genes also encode 
for a large family of distinct polypeptides, with 22 genes 
yielding a total of 18 proteins (Additional file 1: Table S2). 
A typical spectrum of histone H2B from healthy 
CD19+ B cells is shown in Fig. 3a. While a number H2B 
species displayed altered abundance in the CLL patient 
samples, these species were all very low in abundance 
and are also highly modified (Table 1).
Bladder and breast cancer models
In the bladder cancer cell lines, there was a progressive 
increase in the H2B species with a M.W. of 13,775 Da, 
which represents the di-methylated form of H2B 1C, 
as the cells became more aggressive (Additional file  1: 
Table  S6a), although it did not reach statistical signifi-
cance. However, in contrast to the CLL patient samples, 
there were changes in the relative abundance of several 
of the most abundant replication-dependent H2B spe-
cies in the breast cancer cell culture models (Table  2). 
Interestingly, the histone H2B profile in the breast 
cancer cells also showed a change in the abundance of 
methylated forms of H2B 1C (Table  2). In contrast to 
bladder cancer, the di-methylated form decreased in 
the highly malignant M4 cells. On the other hand, the 
mono-methylated form showed a concomitant increase, 
as the breast cancer cells became malignant (Fig. 3b–d; 
Table 2). Also of note is that the profile of the replica-
tion-dependent H2B in the normal bladder and breast 
epithelium differs dramatically from the profile of the 
normal B cells (Fig. 4). This suggests that there may be 
important tissue-specific changes in the complement of 
this histone.
Global changes in histone H3 species in leukemic 
and cancer cells
The global analysis of histone H3 is complicated by a 
number of factors. First, under the LC conditions used, 
H3 elutes in two distinct peaks (data not shown). Hence, 
spectra from these peaks have been analyzed separately. 
These populations of histone H3 will be referred to as peak 
1 (retention time ~36  min) and peak 2 (retention time 
~42 min) based on the order in which they elute from a 
C18 column. Second, histone H3 is the most highly modi-
fied of the core histones. In particular, the high degree 
of methylation on histone H3 leads to the appearance of 
numerous peaks that are separated by 14 Da (Fig. 5a, g).
Table 2 Histone isoforms that are modified among the breast cancer cell lines with FDR < 0.05
The molecular weight as listed may be attributed to either of the histone informs listed or to a mixture of these.  represents that the isoform is increased or 
decreased in a linear manner to cancer agression.  indicates that the isoforms are increased or decreased in more or less aggressive cell lines.  indicates 
that the isoform is changed in a non-linear manner among the cell lines.  represents that the level of isoform is high/low in the normal/immortalized cell line 
but decreases/increases in the aggressive cell lines respectively.  indicates that the expression of the isoform drops in the most aggressive cell line
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Histone H3 Peak 1
Chronic lymphocytic leukemia
A representative spectrum of peak 1 histone H3 is shown 
in Fig. 5a. We observed down-regulation of several peak 
1 histone H3 species in the CLL tissue samples (Table 1). 
Intriguingly, while changes in H3 acetylation and meth-
ylation have been linked to a number of cancers, the most 
significantly down-regulated species in peak 1 were also 
phosphorylated (Fig. 5b, c) [1–3, 5–7, 21].
Bladder and breast cancer models
Comparison of the peak 1 histone H3 profiles in the series 
of bladder cancer cell lines indicated that these histones 
were largely unchanged. The only species that increased 
Fig. 3 Histone H2B isoforms altered in CLL. a A representative histone H2B spectrum. The peaks that are significantly changed in CLL, bladder 
and breast cancer cells are highlighted with arrows (CLL‑green, bladder‑red and breast‑blue). b A spectrum showing a change in some of the H2B 
isoforms in breast cancer. The isoforms that are most significantly changed have their respective molecular weight written on top of the peak. c, 
d Histograms representing the relative abundance of the peaks with molecular weight ~13,759 and ~13,775 Da. The relative abundance of each 
isoform has been determined as described in Fig. 2b
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in abundance with cancer aggression were unmodified 
and monomethylated versions of H3.2. However their 
adjusted p-values did not reach statistical significance. 
A few of the peak 1 histone H3 species changed in the 
breast cancer cell lines. The most significantly altered 
species was a decreased level of the mono-methylated, 
mono-phosphorylated form of the lone histone H3 iso-
form found in histone cluster 3 (H3/3 or H3.1t, Table 2). 
Intriguingly, the abundance of this species, which was 
originally thought to be testis-specific, was also sig-
nificantly down-regulated in the CLL patient samples 
(Table 1) [22, 23]. Some of the species that are altered in 
bladder and breast cancer are shown in Fig. 5d–f.
Histone H3 Peak 2
Chronic lymphocytic leukemia
The peak 2 population of histone H3 contained an 
entirely different complement of species and, based solely 
on the masses observed, there is no obvious explana-
tion of why this pool of molecules has a distinct LC elu-
tion profile (Fig.  5g). When comparing peak 2 H3 from 
healthy and CLL B cells, many species showed a statis-
tically significant change in abundance (Table  1). Nota-
bly, many phosphorylated forms of H3.1t with differing 
degrees of methylation were altered.
Bladder and breast cancer models
As observed with peak 1, the histone H3 pool from peak 
2 was also not largely different in either bladder or breast 
cancer cells. The only species that showed a statisti-
cally significant change in breast cancer cells were the 
highly modified forms of H3.1 (Table  2). In the bladder 
cancer cell lines, only the ummodifed form of histone 
H3.2 showed an increased level in aggressive cell lines, 
though it did not reach statistical significance (Additional 
file 1: Table S6a).
Global changes in histone H4 species in leukemic 
and cancer cells
Chronic lymphocytic leukemia
Among the core histones, histone H4 contains the least 
variation. There are no replication-independent forms 
of histone H4 and of the 14 replication-dependent H4 
genes, 12 encode identical protein products. The other 
two genes encode minor, but detectable, forms of H4 
(Additional file 1: Table S4). Similar to the situation with 
H3, comparison of healthy and CLL B cells showed that 
H4 levels were mostly unchanged, with 11 of the low 
abundance H4 species showing a statistically significant 
change (Table 1).
Bladder and breast cancer models
Relative to the immortalized normal bladder epithe-
lial cells, there was some alteration of low abundance 
H4 species in the bladder cancer cells (Additional file 1: 
Table S6a). Some of the isoforms that changed in abun-
dance are shown in Fig.  6b–d. However, the M1 to M4 
breast cancer cell lines demonstrated dramatic changes in 
high abundance peaks (Fig. 6e–g; Table 2). Most apparent 
was the increased abundance of the di-methylated and 
mono-acetylated form of H4, with a molecular weight 
of 11,348 (Fig.  6e). There were also increased amounts 
of forms of H4 that contained higher levels of acetyla-
tion (Table 2). As changes in the acetylation state of H4 
Fig. 4 Profile of the replication‑dependent H2B isoforms in our different model systems. LC/MS spectrum of histone H2B isolated from normal 
B‑cells, hTERT immortalized bladder epithelium and immortalized breast epithelium (as indicated)
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lysine 16 has been shown to be a hallmark of many can-
cers, we sought to identify which residue(s) were becom-
ing acetylated as the breast cancer cell lines became 
more metastatic. Western blot analysis using antibodies 
recognizing acetylation at the 4 sites of acetylation on 
the NH2-terminal tail of H4 indicated that the increased 
acetylation observed is primarily due to the modification 
of lysine 5 (Fig. 6h). Notably, the acetylation of lysine 16 
Fig. 5 Histone H3 isoforms altered in leukemic and cancer cells. a A representative histone H3 peak 1 LC/MS spectrum. The peaks that are signifi‑
cantly changed in CLL, bladder and breast cancer cells are highlighted with arrows (CLL‑green, bladder‑red and breast‑blue). b, c Representative 
spectrum and histogram, respectively, showing the relative decrease in abundance of the peak with molecular weight ~15,510 Da in CLL B cells. The 
relative abundance of each isoform has been determined as described in Fig. 2b. d, e Representative spectrum and histogram, respectively, show‑
ing the relative abundance of the peak with molecular weight ~15,296 Da in bladder cancer. f A spectrum representing the decreased abundance 
of the peak with molecular weight ~15,476 Da in breast cancer cells. g A representative histone H3 peak 2 LC/MS spectrum. The peaks are labeled 
as described above
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Fig. 6 Histone H4 isoforms altered in leukemic and cancer cells. a A representative histone H4 LC/MS spectrum. The peaks that are significantly 
changed in CLL, bladder and breast cancer cells are highlighted with arrows (CLL‑green, bladder‑red and breast‑blue). b–d Representative spectrum 
(b) and histograms representing the relative abundance of the peaks with molecular weight ~11,390 Da (c) and ~11,406 Da (d) in bladder cancer 
cells. The relative abundance of each isoform has been determined as described in Fig. 2b. e–g Representative spectra (e) and histograms repre‑
senting the relative abundance of the peaks with molecular weight ~11,306 Da (f) and ~11,348 Da (g) respectively in breast cancer cells. h Western 
blot analysis of histones isolated from the M1–M4 cell lines (as indicated). Western blots were probed with antibodies recognizing the indicated 
sites of acetylation on the NH2‑terminal tail of histone H4. The bottom panel shows the Ponceau S staining of the blot prior to antibody incubation
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does not appreciably change across these cell lines. While 
H4 lysine 5 acetylation clearly correlated with malignant 
phenotype of the breast cancer cell lines, it will be impor-
tant to determine whether this modification plays a caus-
ative role.
Discussion
Previous global analyses of histones in cancer have 
focused on the post-translational modification patterns 
of histones H3 and H4. These studies have identified sev-
eral specific modifications that strongly correlate with 
tumorigenesis. In particular, decreases in the levels of 
H4 lysine 16 acetylation and lysine 20 methylation and 
H3 lysine 18 acetylation, lysine 4 methylation and lysine 
9 methylation have been seen in a large number of tumor 
types and tumor cell models [1, 5, 6, 8, 21, 24–27]. How-
ever, we have found that the abundance of the post-trans-
lationally modified forms of H3 and H4 are quite stable 
across a large number of CLL patient samples with most 
of the changes limited to relatively low abundance spe-
cies. This suggests that alterations of H3 and H4 are not 
universally hallmarks of malignant transformation.
The paucity of changes in high abundance species 
observed in CLL patient samples may have a number of 
explanations. From a biological perspective, CLL may be 
distinct from the limited range of other malignancies that 
have been explored, such as prostate and lung cancer. 
There may also be technical reasons that could prevent 
our analyses from detecting such changes. Our study has 
relied on mass spectrometry rather than immunological 
methods. This allows us to measure the relative abun-
dance of a specifically modified histone species but does 
not allow us to localize the modifications to a specific 
residue. Hence, if there were a decrease in the level of H4 
lysine 16 acetylation in the CLL cells but a concomitant 
increase in the acetylation of another lysine residue on 
H4, there would be no net change in acetylation detected.
There was a more dramatic change in the profile of his-
tone H4 in the breast cancer cell lines. There was a much 
higher level of the 11,349 Da species in the M4 cells relative 
to the M1 cells. Based on this molecular weight, this species 
is likely to be the di-methylated/mono-acetylated form of 
H4. Based on previous analyses, the majority of this species 
typically contains H4 lysine 20 dimethylation and lysine 16 
acetylation [4]. Progressive increases in this methylated/
acetylated species of H4 across the spectrum of aggressive-
ness of this series of breast cancer cell lines are contrary to 
immunohistochemical analysis of breast tumor samples 
[6]. However, while we appreciate that no cell culture sys-
tem fully recapitulates the complexity of human disease 
and that there are differences in the information obtained 
between mass spectrometry and immunohistochemical 
techniques, these differences might give us insight into the 
behavior of different subtypes of breast cancer.
One of the most important reasons for the use of mass 
spectrometry to characterize the histone proteome 
is that it is an unbiased approach that does not rely on 
the existence of modification-specific antibodies. As 
there are relatively few immunological reagents specific 
for the characterization of post-translational modifica-
tions on histones H2A and H2B, our analysis is the most 
comprehensive study of these histones in cancer, to date. 
Our results indicate that the patterns of histones H2A 
and H2B found in both primary tumor tissue samples 
and cancer cell line models are highly dynamic. These 
changes were observed both between healthy and can-
cer cells and between different types of cancer cells. For 
example, the pattern of H2B observed in B cells was very 
different from that observed in the solid tumor cell lines. 
This suggests the possibility that there may be tissue spe-
cific variations in the patterns of histone H2A and H2B 
species.
The dynamic nature of histone H2A is not limited to 
its pattern of post-translational modifications. We also 
detect a wide range of variation in the abundance of spe-
cific replication-dependent isoforms of histone H2A. 
While the functional analysis of these distinct replica-
tion-dependent H2A isoforms is only beginning, the 
observation that their abundances are altered in primary 
tumor tissue supports the intriguing possibility that they 
may encode functionally distinct molecules [16, 17].
The most clinically relevant species in the histone com-
plement of CLL cells may be that with a molecular mass 
of 14,063 Da. The CLL patient samples could be divided 
into two groups based on the presence or absence of 
this species. Those patients with a detectable level of 
this species had a significantly shorter time to treat-
ment; its prognostic relevance will need to be verified 
in an independent dataset. Additionally, identification 
of the molecular make-up of this species will be needed 
to determine whether this form of histone H2A plays a 
functional role in disease progression.
Conclusions
We have performed a comprehensive proteomic analy-
sis of the core histones from CD19+ B cells from healthy 
individuals and the malignant counterpart in CLL patient 
samples as well as from bladder and breast cancer cell 
line models. Using LC/MS, we have quantified the rela-
tive abundance of every detectable histone peak to iden-
tify histone species whose abundance correlates with the 
presence or severity of disease. Our results identified 
interesting candidates whose levels show a significant 
correlation to disease aggression and can be explored 
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further. In addition, we demonstrated that the abundance 
of the vast majority of histone species do not significantly 
change in primary tumor samples and cell model sys-
tems suggesting that at least some malignancies are not 
accompanied by large-scale alterations in the global his-
tone proteome.
Methods
Cell lines and culture conditions
Peripheral blood was obtained from patients diagnosed 
with CLL by NCI 1996 criteria (Ref: Cheson et al., Blood. 
1996; 87(12):4990–7) or from healthy individuals under 
protocols approved by the Ohio State University Institu-
tional Review Board, according to the Declaration of Hel-
sinki. Clinical status of CLL patients varied, but all CLL 
samples contained elevated lymphocyte count (>30,000 
CD19+  cells/uL). CD19+  cells were obtained by nega-
tive selection using reagents from StemCell Technolo-
gies (Vancouver BC). M1–M4 cells were a gift from Dr. 
Tsonwin Hai. The cells were grown in DMEM/F-12 with 
5 % horse serum (Invitrogen), 0.029 M sodium bicarbo-
nate (Sigma), 10  mM HEPES (Sigma), 10  µg/ml insulin 
(Sigma), 10 ng/ml EGF (Millipore), 0.5 µg/ml hydrocor-
tisone (Sigma), 100  ng/ml cholera toxin (Calbiochem) 
and 1 % penicillin/streptomycin (Sigma). hTERT cells are 
immortalized breast epithelial cells, RT4 cells are trans-
formed but non-malignant, T24 cells are malignant but 
non-metastatic and UM-UC-3 cells are malignant and 
highly metastatic. The cells were grown in DMEM, sup-
plemented with 10 % FBS and 1 % penicillin/streptomy-
cin (Sigma). All the cell types as described above were 
incubated at 37 °C in a humidified atmosphere with 5 % 
CO2 and 95 % air.
Mass spectrometry
Histones were prepared with standard acid extraction 
procedure as described [28]. Extracted histones were 
subjected to LC–MS analysis. Characterization was per-
formed by HPLC separation (Dionex, Waltham, MA) in 
line with either a MicroMass Q-TOF (MicroMass, Mil-
ford, MA) or AmaZon ETD (Burker, Billerica, MA) mass 
spectrometers.
For the Q-TOF MS analysis, approximately 20  μg of 
extracted histones were HPLC separated on a Dionex 
Ultimate 3000 capillary/nano HPLC (Dionex, Waltham, 
MA) fitted with a 1.0 ×  150  mm C18 column (Discov-
ery Bio wide pore C18 column, 5 μm, 300 Å, Supelco, 
USA) as described previously by Wang et al. [29]. Mobile 
phase A contained 0.05  % TFA (aq) (Pierce, Rockford, 
IL). Mobile phase B contained 0.05 % TFA in acetonitrile 
(EMD Millipore, Billerica, MA). Initial conditions were 
20 % B, with linear increases to 30 % at 2 min, 35 % at 
10 min, 50 % B at 30 min, 60 % at 35 min and 95 % at 
36  min. The column was washed at 95  % B for 4  min. 
Column equilibration was conducted at the initial con-
ditions for 15  min. Total run time was 55  min. Blank 
injections of the same gradient were made between 
each sample injection. The mass range (500-2500 m/z) 
was scanned every 0.6  s in positive ion mode. A repre-
sentative raw spectrum for each histone variant has been 
provided in Additional file  2: Fig.  S2. Savitzky Golay 
smoothing (smooth window  ±  3 channels, 2 cycles), 
mass deconvolution (MaxEnt algorithm, 1.0  Da/chan-
nel resolution, 0.750 Da uniform Gaussian width at half 
height damage model, 33 % left right minimum intensity 
ratios, iterate to convergence) and mass analysis were 
conducted using the MassLynx software 4.0 (Waters 
Corp., Milford, MA).
For AmaZon ETD analysis, approximately 100  ng 
of extracted histones were subjected to a modified 
LC–MS method described by You et  al. [30]. HPLC 
separation was performed on a Dionex Ultimate 3000 
capillary/nano HPLC (Dionex, Waltham, MA) fitted 
with a 0.3 ×  150  mm Magic C8 column (5 μm, 300 Å, 
Michrom Bioresources, Auburn, CA). Mobile phases 
were HPLC water (J.T. Baker, Center Valley, PA) and 
acetonitrile (EMD Millipore, Billerica, MA) each sup-
plemented with 0.5  % formic acid (v/v, Acros Organics, 
Waltham, MA). Initial conditions were 20  % B held for 
5  min, the gradient increased to 30  % B at 25  min and 
35 % B at 65 min each with a convex curvature of 2. From 
65 to 78 min, the gradient increased from 35 to 48 % B 
with a convex curvature of 4. Column equilibration at the 
initial conditions was conducted 12 min. Total run time 
was 90  min. Blank injections of the same gradient were 
made between each sample injection. A 500–2500 m/z 
mass range was scanned every 0.2 s in positive ion mode. 
A representative raw spectrum for each histone variant 
has been provided in Additional file  2: Fig.  S3. Savitzky 
Golay smoothing (3 m/z width, 2 smooth cycles), Maxi-
mum Entropy deconvolution (data point spacing auto 
m/z, instrument peak width 0.3, resolution normal) and 
data analysis was conducted using the Bruker ESI Com-
pass Data Analysis 1.3 software for AmaZon (ver 4.0 SP4, 
Bruker, Billerica, MA).
For quantitation of an isoform, the peak intensities of 
all the isoforms corresponding to a particular histone 
were pooled. The abundance of a particular isoform 
was then calculated relative to the pooled intensity of all 
detectable forms of that histone. A given peak was there-
fore quantitated relative to the total amount of histone 
present in the sample. The same approach was followed 
for the results derived from both the Q-Tof and Amazon 
mass spectrometers.
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Statistical analysis
For each histone, the expression for a particular species 
was measured relative to the total expression across all 
species. The nonparametric Wilcoxon rank sum test was 
used to compare (1) the proportion expressed between 
normal donor and CLL patient samples and (2) the pro-
portion expressed between patients samples with CLL 
and Zap70 positive (>20  %) versus negative protein. In 
these patients, time to treatment was measured from the 
date of diagnosis until the date of first treatment, censor-
ing those who had not yet started treatment at the date of 
last follow-up. Associations between expression of a spe-
cies (using median expression to group patients as high 
and low expressers) and time to treatment were evaluated 
using the score test from proportional hazards models; 
estimates of hazard ratios with confidence intervals were 
estimated from the model. Difference in time to treat-
ment between high and low expressers for a particular 
species is shown graphically in a Kaplan–Meier plot. All 
tests are 2-sided and statistical significance was declared 
when the false discovery rate (FDR) adjusted p-value was 
less than 0.05, allowing for 5 % of the significant tests to 
be false positives. If none of the variants are statistically 
significant when applying the multiple testing corrections 
then it may be possible that the findings are false posi-
tives. However, to provide complete information, all the 
isoforms have been ordered for each analysis from small-
est to largest p-value without any correction, with results 
corresponding to the smallest p-value as most reliable. 
The results have been sorted as separate tables based on 
if the isoforms were significant at least at the raw p-value 
levels (Additional file 1: Tables S5a, S6a and S7a) or non-
significant even at raw p-value levels (Additional file  1: 
Tables S5b, S6b and S7b). A few of the isoforms had an 
FDR  <  0.05, but were unidentified and therefore omit-
ted from the study. The differences in expression across 
breast and bladder cell lines with varying degrees of 
aggressiveness were screened using one-way ANOVA. 
The cell lines were analyzed in triplicates and error bars 
represent the standard error of mean between the sam-
ples. All statistical analyses were conducted using the 
SAS (University Edition) statistical software package 
(SAS Institute Inc., Cary, NC).
Western Blotting: The M1–M4 cell lines were grown 
as described above. The cells were seeded in equal num-
bers, harvested after 48  h and histone preparation was 
carried out as described elsewhere (ref 29). The histones 
were quantitated using Bradford assay and about 20 μg 
of protein was used for western analysis. All the antibod-
ies used in the analysis were purchased commercially 
(Abcam, Cambridge, MA). Briefly, the samples were 
loaded on 12.5  % polyacrylamide gels, transferred to 
PVDF membranes and Ponceau stained. The images were 
taken to confirm the equal loading followed by block-
ing in 5 % skimmed milk. The blots were the incubated 
in respective primary and HRP-conjugated secondary 
antibodies (G E Healthcare, UK) in 1:1000 and 1:5000 
dilutions respectively. After each incubation, the blots 
were washed three times with TBST and finally devel-
oped using Pierce™ ECL Western Blotting Substrate (Life 
Technologies). The blots were then exposed to X-ray film 
for 60 s (Denville Scientific Inc, South Plainfield, NJ). The 
process was repeated three times using different passages 
of cell lines to ensure reproducibility.
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